Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Others

Bioregenx (BRGX) Non-cash Items (2024 - 2025)

Bioregenx has reported Non-cash Items over the past 2 years, most recently at $37.4 million for Q4 2025.

For Q4 2025, Non-cash Items rose 3241.73% year-over-year to $37.4 million; the TTM value through Dec 2025 reached $37.4 million, up 3241.73%, while the annual FY2025 figure was $37.4 million, 3241.73% up from the prior year.
Non-cash Items for Q4 2025 was $37.4 million at Bioregenx, down from $41.6 million in the prior quarter.
Over five years, Non-cash Items peaked at $41.6 million in Q3 2025 and troughed at $1.1 million in Q1 2024.